An ISO 9001:2008 & GMP certified company  | info@arlakbiotech.com  |  +91-9803023099, 7696263636  |  1800-121-6263 (Toll Free) 

FYPOD-50 D/S


COMPOSITION:

CEFPODOXIME ORAL SUSPENSION IP

Categories: , .
Description

Clinical Pharmacology

Absorption and Excretion:

Cefpodoxime Proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime.The oral administration of 100 mg of Cefpodoxime Proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically. Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours. There is minimal metabolism of cefpodoxime in vivo.

Pharmacokinetics of Cefpodoxime

Over the recommended dosing range,the rate and extent of cefpodoxime absorption exhibited dose-dependency; dose-normalized Cmax and AUC decreased by up to 32% with increasing dose. Over the recommended dosing range, the Tmax was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.

INDICATIONS:-

Urinary tract infection

sinusitis

post operative infection

gynacological infection

skin & soft tissue infection

community acquired pneumonia

chronic bronchitis

Contact Us
close slider